It is believed that patients with decreased glomerular filtration rate have stronger association between serum uric acid levels and increased risk of cardіоvascular disease. However, it is unclear whether the presence of concomitant chronic kidney disease modifies the xanthine metabolism. The aim of this study was to examine xanthine metabolism violations in chronic heart failure (CHF) patients with concomitant chronic kidney disease (CKD), and evaluate its impact on uric acid levels and xanthine oxidase activity.
View Article and Find Full Text PDFA total of 176 patients with hypertensive disease (HD) were examined. The obtained data show that there is a relationship of the systolic function to autonomic regulation in HD patients. Those patients having displayed a decline in the systolic function had lower indices for the heart's rhythm variability, which fact suggested an unfavorable prognosis, with the decline in the activity of autonomous nervous regulation referrable to a greater extent to nervus sympathicus.
View Article and Find Full Text PDFIn an acute pharmacological test in 13 healthy volunteers (24 +/- 4) years old effects were studied of propranolol, 40 mg/50 kg body mass, on the sympathovagal regulation and phase patterns of the cardiac cycle. The study was made with the aid of the computer electrocardiograph "Cardiolab 2000" at the height of the propranolol effect by standard methods. The state of the sympathovagal regulation was assessed by the heart's rhythm variability technique with respect to the spectrum lowfrequency and highfrequency ranges powers.
View Article and Find Full Text PDFAs many as 29 patients with arterial hypertension were examined. All patients were instituted a 3-week antihypertensive therapy with metoprolol. Against the background of intake of metoprolol, there occurs a rise in indices for variability of the heart's rhythm.
View Article and Find Full Text PDFOverall sixty patients with hypertensive disease were examined for clinical effectiveness of the prolonged-action inhibitor angiotensine-converting enzyme renitek (enalapril maleate, MJD). The treatment schedule included placebo over two weeks, renitek as monotherapy, 20 mg daily, over 6 weeks, if the patients failed to derive any benefit from the therapy, they were placed on a 4-week combined therapy of renitek plus hydrochlorothiazide. Renitek was found to dispel cardialgias, reduce frequency of attacks of cardiac angina.
View Article and Find Full Text PDF